12:11 29/01/2015 Arena Pharmaceuticals, Inc. Analyst Rating Update
Arena Pharmaceuticals, Inc. Analyst Rating Update
Stafford Daily - Jan 29, 2015
Research firm Zacks has rated Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and has ranked it at 3, indicating that its shares are a Neutral.

20:03 22/01/2015 Arena Pharmaceuticals to Raise Fund Via Share Issuance
Arena Pharmaceuticals to Raise Fund Via Share Issuance
Zacks.com - Jan 22, 2015
Arena Pharma intends to utilize the net proceeds from the offering for the clinical and preclinical development of its pipeline candidates.

14:37 22/01/2015 Arena Pharmaceuticals (ARNA) Stock Crippled By Risk, Dilution
Arena Pharmaceuticals (ARNA) Stock Crippled By Risk, Dilution
Investorplace.com - Jan 22, 2015
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock has been on quite a roller coaster ride in 2015. A few weeks ago, ARNA shares roared 76% higher in a single day after positive early-stage trials for an autoimmune disease treatment gave investors a ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Looks Forward To Maximizing Its ... - USMarketsDaily (blog)
Arena Pharmaceuticals Coverage Initiated by Analysts at RBC Capital (ARNA) - sleekmoney

22:18 21/01/2015 Belviq IMS Gains Consistent With Symphony (ARNA)
Belviq IMS Gains Consistent With Symphony (ARNA)
Seeking Alpha - Jan 21, 2015
Belviq retains 40% share compared to Qsymia and Contrave, although both post better than expected numbers. Due to discounting, Arena guided to 35-45% less revenue for Q4. Whether that may be recouped in Q1 2015 may be determined by Contrave's ...

19:57 14/01/2015 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Initiates Phase 2 Clinical Trials
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Initiates Phase 2 Clinical Trials
Inside Trade - Jan 14, 2015
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it has initiated the patient dosing in a Phase 2 clinical trial of ralinepag which is an oral, non-prostanoid prostacyclin (IP) receptor agonist that is intended for the treatment of pulmonary ...
Short Interest of Arena Pharmaceuticals, Inc. Drops - Stafford Daily
Arena Pharmaceuticals Doses for Cardiovascular Study - Zacks.com

13:41 14/01/2015 Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Pre-Market Leader Stock
Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Pre-Market Leader Stock
TheStreet.com - Jan 14, 2015
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.

12:45 12/01/2015 Arena Pharmaceuticals (ARNA) in Focus: Stock Falls 5.7%
Arena Pharmaceuticals (ARNA) in Focus: Stock Falls 5.7%
Zacks.com - Jan 12, 2015
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) saw a big move last session, as the company's shares fell by nearly 6% on the day.
Arena Pharmaceuticals (ARNA) in Focus: Stock Falls 5.7% - Tale of the Tape - Nasdaq

21:38 08/01/2015 Arena Pharmaceuticals Inc.'s Phase 1 Data is Worth $550 Million!?
Arena Pharmaceuticals Inc.'s Phase 1 Data is Worth $550 Million!?
Motley Fool - Jan 8, 2015
Arena Pharmaceuticals' (NASDAQ: ARNA ) stock jumped 76% Wednesday after the company released clinical trial data on its autoimmune drug APD334.
ARNA Stock Pops, And There's Plenty More Where That Came From - Investorplace.com
Arena's APD334 Has Real Blockbuster Potential (ARNA) - Seeking Alpha

14:48 07/01/2015 Arena Pharmaceuticals (ARNA) Showing Signs Of A Dead Cat Bounce Today
Arena Pharmaceuticals (ARNA) Showing Signs Of A Dead Cat Bounce Today
TheStreet.com - Jan 7, 2015
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.

13:03 06/01/2015 Why Arena Pharmaceuticals, Inc. Stock Slumped 17% in December
Why Arena Pharmaceuticals, Inc. Stock Slumped 17% in December
Motley Fool - Jan 6, 2015
What: Shares of Arena Pharmaceuticals (NASDAQ: ARNA ) , a biopharmaceutical company primarily focused on developing drugs for weight control management purposes, slumped 17% in December, based on data from S&P Capital IQ, after a rival received ...